Перетащите, чтобы изменить положение крышки
Следую
О нас
Alzheimer’s disease (AD) remains one of the most capital-intensive and failure-prone areas in biopharma. Decades of high-profile setbacks created what many termed the Alzheimer’s graveyard. Yet recent approvals targeting amyloid biology have demonstrated a critical shift: regulatory pathways are viable—but only when programs are designed with precision and foresight.
Следую
(19)
Подписчики
(1)
Обрезать аватар
